Stroke, idiopathic thrombocytopenic purpura and avatrombopag: two cases of coincident events

doi:10.1007/s10072-025-08186-8

. 2025 Aug;46(8):4051-4055.

doi: 10.1007/s10072-025-08186-8. Epub 2025 Apr 25.

Stroke, idiopathic thrombocytopenic purpura and avatrombopag: two cases of coincident events

Bernat Boy¹, Gloria Iacoboni², David Valcárcel², Carlos Molina^{3

4}, Marc Rodrigo-Gisbert^{5

6}

Affiliations

¹ Department of Neurology, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron 110-129, Barcelona, 08035, Spain.
² Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain.
³ Stroke Unit, Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain.
⁴ Vall d'Hebron Institut de Recerca, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
⁵ Stroke Unit, Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain. marc.rodrigo@vallhebron.cat.
⁶ Vall d'Hebron Institut de Recerca, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. marc.rodrigo@vallhebron.cat.

PMID: 40278977
DOI: 10.1007/s10072-025-08186-8

Stroke, idiopathic thrombocytopenic purpura and avatrombopag: two cases of coincident events

Bernat Boy et al. Neurol Sci. 2025 Aug.

. 2025 Aug;46(8):4051-4055.

doi: 10.1007/s10072-025-08186-8. Epub 2025 Apr 25.

Authors

Bernat Boy¹, Gloria Iacoboni², David Valcárcel², Carlos Molina^{3

4}, Marc Rodrigo-Gisbert^{5

6}

Affiliations

¹ Department of Neurology, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron 110-129, Barcelona, 08035, Spain.
² Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain.
³ Stroke Unit, Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain.
⁴ Vall d'Hebron Institut de Recerca, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
⁵ Stroke Unit, Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain. marc.rodrigo@vallhebron.cat.
⁶ Vall d'Hebron Institut de Recerca, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. marc.rodrigo@vallhebron.cat.

PMID: 40278977
DOI: 10.1007/s10072-025-08186-8

No abstract available

Keywords: Avatrombopag; Idiopathic thrombocytopenic purpura; Stroke.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: This research adhered to the tenets of the Declaration of Helsinki. Competing interests: Authors report no conflicts of interest. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Markham A (2021) Avatrombopag: A review in thrombocytopenia. Drugs 81:1905–1913. https://doi.org/10.1007/s40265-021-01613-y - DOI - PubMed - PMC
1. Bussel JB et al (Jun. 2014) A randomized trial of Avatrombopag, an investigational thrombopoietin- receptor agonist, in persistent and chronic immune thrombocytopenia. Blood 123:3887–3894. https://doi.org/10.1182/blood-2013-07-514398
1. Jurczak W et al (Nov. 2018) Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia Br J Haematol 183(3):479–490. https://doi.org/10.1111/bjh.15573
1. Kuter DJ (May. 1 2022) The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Churchill Livingstone https://doi.org/10.1016/j.blre.2021.100909
1. Rodeghiero F (Jan. 2016) Is ITP a thrombophilic disorder? Am J Hematol 91(1):39–45. https://doi.org/10.1002/ajh.24234

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Springer

[1] Markham A (2021) Avatrombopag: A review in thrombocytopenia. Drugs 81:1905–1913. https://doi.org/10.1007/s40265-021-01613-y - DOI - PubMed - PMC

[2] Markham A (2021) Avatrombopag: A review in thrombocytopenia. Drugs 81:1905–1913. https://doi.org/10.1007/s40265-021-01613-y - DOI - PubMed - PMC

[3] Bussel JB et al (Jun. 2014) A randomized trial of Avatrombopag, an investigational thrombopoietin- receptor agonist, in persistent and chronic immune thrombocytopenia. Blood 123:3887–3894. https://doi.org/10.1182/blood-2013-07-514398

[4] Bussel JB et al (Jun. 2014) A randomized trial of Avatrombopag, an investigational thrombopoietin- receptor agonist, in persistent and chronic immune thrombocytopenia. Blood 123:3887–3894. https://doi.org/10.1182/blood-2013-07-514398

[5] Jurczak W et al (Nov. 2018) Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia Br J Haematol 183(3):479–490. https://doi.org/10.1111/bjh.15573

[6] Jurczak W et al (Nov. 2018) Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia Br J Haematol 183(3):479–490. https://doi.org/10.1111/bjh.15573

[7] Kuter DJ (May. 1 2022) The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Churchill Livingstone https://doi.org/10.1016/j.blre.2021.100909

[8] Kuter DJ (May. 1 2022) The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Churchill Livingstone https://doi.org/10.1016/j.blre.2021.100909

[9] Rodeghiero F (Jan. 2016) Is ITP a thrombophilic disorder? Am J Hematol 91(1):39–45. https://doi.org/10.1002/ajh.24234

[10] Rodeghiero F (Jan. 2016) Is ITP a thrombophilic disorder? Am J Hematol 91(1):39–45. https://doi.org/10.1002/ajh.24234

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Stroke, idiopathic thrombocytopenic purpura and avatrombopag: two cases of coincident events

Affiliations

Stroke, idiopathic thrombocytopenic purpura and avatrombopag: two cases of coincident events

Authors

Affiliations

Conflict of interest statement

Similar articles

References

Publication types

LinkOut - more resources

Full Text Sources